Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-12-02

Clinical Trial Update: Tocilizumab Plus a Short Prednisone Taper for GCA [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating tocilizumab with a short prednisone taper for giant cell arteritis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PREDNISONE (Prednisone)
  • Tocilizumab (tocilizumab)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Giant Cell Arteritis | Phase 4 | Status: COMPLETED | Results posted: 2022-12-02